(SOD), catalase (CAT), and glutathione peroxidase (GPx). However, when the level of ROS exceeds the defense mechanisms, these enzymes may be itself oxidatively damaged. 12 Indeed, anti-CAT autoantibodies' production was described in human autoimmune pathologies such as systemic lupus erythematosus (SLE) and arthritis rheumatoid (AR). 13 However, there is no report about the oxidative effects of ROS on CAT enzyme in thyroid disorders.
In this study, we determined whether oxidative modification of the CAT induced by MDA and H 2 O 2 enhanced the reactivity of plasmas of patients with GD and healthy controls by comparison with the reactivity toward the native enzyme.
| PATIENTS AND ME THODS

| Ethics approval
The performed experimental protocols and consent forms were in accordance with the guidelines of the Declaration of Helsinki and approved by the local Ethics Committee of the Hedi Chaker University Hospital of Sfax, Tunisia.
| Patients recruitment
A total of 34 untreated Tunisian patients with GD were recruited from the department of endocrinology inpatient and outpatient clinics, Hedi Chaker University Hospital of Sfax, Tunisia.
In total, 65 healthy volunteers without familial history of autoimmune diseases and without any recent drug treatments were enrolled in the study (Tables 1 and 2 ).
| Hormonal and antibodies tests
| Measurement of TSH
The evaluation of the TSH level was assessed by enzyme immunoassay using the ELFA technique (enzyme-linked fluorescent assay). VIDAS TSH is an automated assay for the VIDAS system, which enables human TSH in serum or plasma to be quantitatively measured. The assay principle combines the indirect enzyme immunoassay method with a final fluorescent detection (ELFA). All reaction steps are performed by the VIDAS instrument. The disposable Solid Phase Receptacle serves both as a solid phase and as a pipetting device during the assay. Reagents for the assay are all contained in the sealed reagent strips. The results are expressed in µUI/mL.
| Measurement of FT3
The determination of the serum level of FT3 was carried out by a radioimmunoassay method using the RIA-gnost®FT3 kit (CIS bio).
This assay is based on a competition between a radioisotope-labeled antigen and a cold antigen to be assayed for the same amount of antibody. At the bottom of each tube coated with Ac, 50 µL of sample and 1000 µL of the 125I-FT3 tracer solution were successively deposited. After stirring for 120 minutes at room temperature and at a speed between 1120 and 3400 g, the liquid is removed by suction followed by taping on absorbent paper. The measurement of the radioactivity is carried out for one minute using a gamma counter (Wallac). For each series of samples, a calibration curve is established using standard solutions delivered with the kit. The results are expressed in pg/mL.
| Measurement of FT4
The RIA-gnost® FT4 kit is used to evaluate free T4 using antibody-coated tubes in a two-step procedure. The serum sample is first incubated with a polyclonal antibody bound to the solid phase and then removed by decantation. Then, the radioactive tracer is added to lodge the sites of antibodies remaining free after decantation.
At the bottom of each tube coated with Ac, 100 μL of sample and 1 mL of incubation buffer are deposited successively. After stirring for 30 minutes using a horizontal stirrer at room temperature and at a speed between 1120 and 3400 g, the liquid is removed by suction followed by tapping on absorbent paper. Then, 1 mL of the 125I-FT4 tracer solution is deposited and the tubes are stirred again for 60 minutes. After removing the remaining liquid that can adhere to the edge of the tubes by tapping, the measurement of radioactivity is carried out for one minute using a gamma counter (Wallac). For each series of samples, a calibration curve
TA B L E 1 Basic clinical characteristics of Graves' disease patients and healthy controls
Parameters
Control GD Anti-R-TSH (µUI/mL) <2 37 ± 2.9
Note: Statistical analyses were performed using unpaired t test; there were no significant differences between the groups regarding the age (P > .05); and significant differences were found ***P < .001.
TA B L E 2 Catalase activity in plasmas of Graves' disease patients
Test Controls n = 65
GD n = 34
Catalase (U/mg of proteins) 8.73 ± 1.34 3.79 ± 0.76*
Note:
The results are expressed as mean ± SEM Statistical analyses were performed using the unpaired t test, and significant differences were found *P < .05 by comparison with the control group.
was established using standard solutions delivered with the kit.
The results were expressed in pg/mL.
| Measurement of anti-Tg and anti-TPO
The search for anti-thyroid antibodies (anti-Tg and anti-TPO) was performed by an ELISA kit (Orgentec 
| Catalase activity
The method of Aebi 1984 was used to evaluate the CAT activity. 14 
| Oxidative modification of the catalase enzyme
| Enzyme-linked immunosorbent assay (ELISA)
The CAT modification was assessed according to the method of MSEDDI et al. 2017. 7 The optical density (OD) at 405 nm was determined using a micro-ELISA plate reader.
| Protein quantification
Protein Assay Kit from Bio-Rad (France) was used to determine the protein level in the plasmas of patients and controls. The bovine serum albumin served as a standard.
The plasmas are diluted in a volume of 800 µL of sterile water and then added with 200 µL of Bradford reagent. The optical density (OD) is read at 595 nm.
| Statistical analyses
The evaluation of differences between patients and controls regard- 
| RE SULTS
| Evaluation of hormonal and antibodies levels
The evaluation of the level of the thyroid hormones in GD patients'
showed an increase in FT4 and FT3 concomitant with reduced TSH in comparison with healthy controls (P < .001) ( Table 1 ). In addition, high rates of anti-thyroid autoantibodies, anti-TPO, anti-Tg, and anti-TSH-R, were detected in patients compared with controls (Table 1 ).
| Determination of the catalase activity
The plasmatic CAT activity was significantly reduced in patients compared with controls (P < .05) ( Table 2 ).
| Immune response to MDA and H 2 O 2 modified catalase
The plasmatic reactivity toward MDA-modified CAT was higher than the native one in patients with GD (P < .001) ( Figure 1 ). Remarkably, a slight increase in the reactivity toward MDA-modified CAT was also noted in controls (P < .05) (Figure 1) . Nevertheless, the ratio 
| Correlation study
The statistical analyses showed a significantly positive correlation between the reactivity toward the MDA-modified CAT and the level of FT3 hormone (r = .6, P < .001, n = 31) ( Figure 4 ).
| D ISCUSS I ON
Results reported in the present study demonstrate that the CAT activity was reduced in plasmas of patients with GD compared to controls. These data are consistent with several studies also showing a decrease in the CAT activity in sera and plasma of patients with GD. 16, 17 So, the reduced activity of the enzyme may indicate an excessive consumption or structural alterations due to oxidative stress.
In fact, oxidative modifications may alter the function of the enzyme and/or create new epitopes that could generate antibody response.
Several studies supporting this hypothesis showed that the CAT enzyme is a major protein target of the lipid peroxidation product 4-HNE in autoimmune diseases such as the SLE. 18 In order to verify our hypothesis, we evaluate in a comparative way the reactivity of plasmas of patients with GD and healthy controls toward the native ). This radical can lead to the formation of many other reactive species, including the hydroxyl radicals (OH • ), which can readily start the free radical process of lipid peroxidation. 6 Also, thyroid H 2 O 2 involved in the hormone biosynthesis can be turned into the highly reactive hydroxyl radical (OH • ) via the Fenton reaction. [21] [22] [23] The highly reactive OH • is responsible for the abstraction of the hydrogen from lipids that results in the formation of lipid alkyl radical during the initiation of the lipid peroxidation process. During the termination step, unsaturated reactive aldehydes, like MDA and other products, were generated. 24, 25 Indeed, the MDA, one of the most abundant lipid peroxidation-derived aldehydes, can easily diffuse across membranes and can covalently modify proteins in the cytoplasm and the nucleus, far from their site of origin. 26 Moreover, it can bind covalently with proteins to form MDA-modified protein adducts that are immunogenic and may act as neo-autoantigens in initiating a strong autoimmune response. [27] [28] [29] In line with our results, studies by Ben Mansour et al (2008, 2010) demonstrate that the MDA-modified CAT and SOD were better recognized in sera of patients with two autoimmune pathologies than the unmodified form. 13, 15 Besides, Bakala et al (2012) demonstrated that under an oxidative stress condition, the CAT enzyme is more susceptible than other antioxidant enzyme to be affected by the glycation stress in mitochondrial liver extract of rat. 30 The heightened reactivity of IgG autoantibodies against MDAmodified CAT was evidenced in plasmas of patients with GD. It seems that the MDA has a key role in the appearance of new epitopes that could be the target of immune response, which could contribute to the misbalance of the oxidative profile and/or the development of complications of the pathology.
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